IMC Chicago LLC Purchases 2,335 Shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS)
IMC Chicago LLC Purchases 2,335 Shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.IMC Chicago LLC increased its position in shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Get Rating) by 12.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,003 shares of the company's stock after acquiring an additional 2,335 shares during the period. IMC Chicago LLC owned about 5.25% of ProShares UltraShort Nasdaq Biotechnology worth $566,000 as of its most recent filing with the Securities and Exchange Commission.
IMC芝加哥有限責任公司根據其最近提交給美國證券交易委員會的文件，在第二季度將其在ProShares UltraShort納斯達克生物科技公司(納斯達克：BIS-GET評級)的股票頭寸增加了12.5%。該機構投資者持有該公司21,003股股票，在此期間又購買了2,335股。據最近提交給美國證券交易委員會的文件顯示，IMC Chicago LLC持有ProShares UltraShort納斯達克約5.25%的股份，價值566,000美元。
Separately, UBS Group AG grew its stake in shares of ProShares UltraShort Nasdaq Biotechnology by 54.7% in the first quarter. UBS Group AG now owns 1,371 shares of the company's stock worth $33,000 after purchasing an additional 485 shares during the last quarter.
另外，瑞銀集團(UBS Group AG)今年第一季度增持了ProShares UltraShort納斯達克生物科技股份54.7%。瑞銀集團(UBS Group AG)在上個季度增持了485股瑞銀股票後，目前持有1,371股該公司股票，價值33,000美元。
ProShares UltraShort Nasdaq Biotechnology Stock Performance
ProShares超短納斯達克生物科技股表現
ProShares UltraShort Nasdaq Biotechnology stock opened at $21.07 on Friday. ProShares UltraShort Nasdaq Biotechnology has a 52-week low of $18.37 and a 52-week high of $35.64. The firm has a 50 day moving average price of $23.69 and a two-hundred day moving average price of $25.55.
ProShares UltraShort納斯達克生物科技股週五開盤報21.07美元。ProShares UltraShort納斯達克生物科技的52周低點為18.37美元，52周高點為35.64美元。該公司的50日移動均線價格為23.69美元，200日移動均線價格為25.55美元。
ProShares UltraShort Nasdaq Biotechnology Profile
ProShares UltraShort納斯達克生物技術簡介
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.
ProShares超納斯達克生物科技(基金)只尋求一天的投資結果，不尋求較長時期的投資結果。基金尋求扣除費用和費用前的每日投資結果，相當於該指數每日業績的兩倍(200%)。超過一個交易日的基金回報將是這段時間內每一天的回報的複合結果，這很可能與同期納斯達克生物技術指數(該指數)的回報兩倍(200%)不同。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on ProShares UltraShort Nasdaq Biotechnology (BIS)
- MarketBeat: Week in Review 10/31-11/4
- Is Hershey's a Sweet Stock to Buy After a Post-Earnings Dip?
- Datadog Doesn't Belong In The Doghouse
- Mixed Results Actually Bring More Optimism than Risk for AMD
- Nikola Shares Fall Even As EV Maker Beats Q3 Expectations
- 免費獲取StockNews.com關於ProShares UltraShort納斯達克生物技術的研究報告
- MarketBeat：回顧中的一週10/31-11/4
- 好時是一隻在盈利後下跌後買入的甜蜜股票嗎？
- Datadog不屬於狗舍
- 喜憂參半的結果實際上給AMD帶來的樂觀情緒多於風險
- 尼古拉股價下跌，儘管電動汽車製造商第三季度業績好於預期
Receive News & Ratings for ProShares UltraShort Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares UltraShort Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
獲得ProShares UltraShort納斯達克生物科技日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對ProShares UltraShort納斯達克生物技術和相關公司的最新新聞和分析師評級的每日摘要。
譯文內容由第三人軟體翻譯。
